Table 3.

Ongoing studies with RNA-loaded nanoparticles.

Study Name	Phase/Status	Drug	Target	Indication
NCT01591356	I/Active, not recruiting	EphA2 siRNA	EphA2	advanced/recurrent solid tumors
NCT03739931	I/Active and recruiting	mRNA-2752 LNP	OX40L T cell	relapsed/refractory solid tumor or lymphoma
NCT03323398	I-II/Active, not recruiting	mRNA-2416 LNP alone or + durvalumab	OX40L T cell	relapsed/refractory solid tumor or lymphoma
NCT02410733 Lipo-MERIT	I/Active, not recruiting	mRNA RBL001.1, RBL002.2, RBL003.1, RBL004 LIP	NY-ESO-1, MAGE-A3, tyrosinase and TPTE	advanced melanoma
NCT03313778 KEYNOTE-603	I/Active and recruiting	mRNA-4157 LNP alone or +pembrolizumab	20 TAA	unresectable solid tumor
NCT03897881 KEYNOTE-942	I/Active and recruiting	mRNA-4157 LNP + pembrolizumab	20 TAA	resected and high-risk melanoma
NCT04163094 OLIVIA	I/Active and recruiting	W_ova1	3 TAA	resectable ovarian cancer (neoadjuvant and adjuvant)